(Ibuprofen + oxycodone) is under clinical development by Eurofarma Laboratorios and currently in Phase III for Pain. According to GlobalData, Phase III drugs for Pain have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Ibuprofen + oxycodone)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Ibuprofen + oxycodone) overview

A fixed-dose combination of oxycodone and ibuprofen is under development for the treatment of pain after third molar extraction. It is administered in the form of tablet. Oxycodone acts by targeting mu opioid receptor and ibuprofen acts by targeting COX-1 and COX-2 enzyme. It is administered by oral route.

Eurofarma Laboratorios overview

Eurofarma Laboratorios (Eurofarma), is a pharmaceutical company that manufactures and markets therapeutics. The company offers prescription, over-the-counter (OTC), generic and cancer drugs, hospital drugs, and drugs exempt from prescription. Its product, serve all medical specialties and cover various therapeutic classes. Eurofarma’s research and development projects focus on antibiotics, metabolism, and obesity, central nervous system, and oncology. The company operates in Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guatemala, Paraguay, Peru, Venezuela, Mexico, Mozambique and Uruguay. Eurofarma is headquartered in Sao Paulo, Brazil.

For a complete picture of (Ibuprofen + oxycodone)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.